Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Sees Large Growth in Short Interest

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 1,161 shares, a growth of 57,950.0% from the June 30th total of 2 shares. Based on an average daily volume of 3,040 shares, the short-interest ratio is currently 0.4 days. Currently, 0.2% of the shares of the stock are short sold.

Enzon Pharmaceuticals Price Performance

ENZN stock remained flat at $4.35 during midday trading on Friday. The company had a trading volume of 2,271 shares, compared to its average volume of 1,513. Enzon Pharmaceuticals has a fifty-two week low of $1.50 and a fifty-two week high of $9.50. The company’s fifty day simple moving average is $5.22 and its 200 day simple moving average is $5.72. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16. The stock has a market capitalization of $3.22 million, a P/E ratio of -0.64 and a beta of -0.05.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings data on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.